Supplementary Tables S1-S2 from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK<sup>+</sup> Tumors

Amit Dipak Amin,Soumya S. Rajan,Winnie S. Liang, Praechompoo Pongtornpipat, Matthew J. Groysman, Edgar O. Tapia, Tara L. Peters,Lori Cuyugan,Jonathan Adkins,Lisa M. Rimsza,Yves A. Lussier,Soham D. Puvvada,Jonathan H. Schatz

crossref（2023）

引用 0|浏览10

暂无评分

摘要

Supplementary Tables S1-S2. Relative IC50's of ALK+ and ALK- ALCL cell lines to the ALK tyrosine kinase inhibitors crizotinib and ceritinib (S1); ALK Kinase-Domain Sequencing Results (S2).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

Supplementary Tables S1-S2 from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK&lt;sup&gt;+&lt;/sup&gt; Tumors

Supplementary Tables S1-S2 from Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK<sup>+</sup> Tumors